Sage Therapeutics SAGE 深 沪
等待开盘 03-31 09:30:00 美东时间
8.68
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.68
- 总市值 5.44亿
- 52周最高 9.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.62
- 委 比 0.00%
- 总股本 6262.23万
- 历史最高 195.97
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.62
- 每 手 1
- 风险率 1.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Entera Bio Ltd. has appointed Geno J. Germano as its new Chairman, succeeding Gerald Lieberman. Germano, with over three decades of leadership experience in the biopharmaceutical industry, including senior roles at Pfizer and Wyeth, will guide Entera during a pivotal phase as the company advances two oral peptide programs into clinical trials in 2026: a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in...
02-09 13:50
Biogen projects 2026 revenue drop despite Q4 beat
Despite recording better-than-expected Q4 2025 financials, Biogen (BIIB) on Friday projected a mid-single-digit percentage decline in revenue for 2026 compared to last year amid pressure on its multip...
02-06 20:02
Supernus Pharma Q3 revenue rises, partly helped by Sage acquisition
Overview Supernus Q3 2025 total rev rises 9% yr/yr, driven by growth products Company completed acquisition of Sage Therapeutics, contributing to collaboration revenue Operating loss in Q3 due to acqu...
2025-11-05 05:34
Supernus Pharmaceuticals reports third quarter revenue of $192.1 million
Supernus Pharmaceuticals Inc. reported total revenues of $192.1 million for the third quarter of 2025, a 9% increase compared to the same period in 2024. Combined revenues from the company's four grow...
2025-11-05 05:01
Supernus Pharmaceuticals Q2 revenue falls
Overview Supernus Q2 2025 total revenue dips 2% yr/yr to $165.5 mln Adjusted revenue excluding Trokendi XR, Oxtellar XR rises 17% yr/yr Co completes Sage Therapeutics acquisition, enhancing neuropsych...
2025-08-06 05:33
Supernus Pharmaceuticals Clears Antitrust Hurdle For Sage Therapeutics Acquisition In $8.50/Share Cash Offer Plus Up To $3.50/Share In Contingent Value Rights Merger
Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supern
2025-07-28 20:27
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the Hart-Scott-Rodino Act waiting period for its proposed acquisition of Sage Therapeutics. The $8.50 cash offer plus a contingent value right (CVR) for Sage's shares remains subject to certain conditions. The CVR includes potential payments tied to regulatory milestones and U.S. sales targets for ZURZUVAE, with total potential value up to $3.50 per share. The tender offer expires July 30, 2025...
2025-07-28 12:25
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista Pharmaceuticals (NASDAQ:KALV), Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their produ...
2025-07-25 21:23
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock
6 analysts have expressed a variety of opinions on Sage Therapeutics (NASDAQ:SA...
2025-07-08 22:00
Scotiabank Downgrades Sage Therapeutics to Sector Perform, Lowers Price Target to $9.2
Scotiabank analyst George Farmer downgrades Sage Therapeutics (NASDAQ:SAGE) from Sector Outperform to Sector Perform and lowers the price target from $12 to $9.2.
2025-07-08 20:26
